Effect of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function. - Wikidata - awgldk - TriplyDB

Effect of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function.

Effect of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function.

http://www.wikidata.org/entity/Q34575231

about

Mirabegron: a review of recent data and its prospects in the management of overactive bladder Effects of beta3-adrenergic receptor activation on rat urinary bladder hyperactivity induced by ovariectomy The efficacy and tolerability of mirabegron, a β3 adrenoceptor agonist, in patients with symptoms of overactive bladder Unlock the Thermogenic Potential of Adipose Tissue: Pharmacological Modulation and Implications for Treatment of Diabetes and Obesity Drug therapy of overactive bladder--what is coming next?Clinical use of the β3 adrenoceptor agonist mirabegron in patients with overactive bladder syndrome The characterization, current medications, and promising therapeutics targets for premature ejaculation Classification of Therapeutic and Experimental Drugs for Brown Adipose Tissue Activation: Potential Treatment Strategies for Diabetes and Obesity Discovery history and clinical development of mirabegron for the treatment of overactive bladder and urinary incontinence.Enhancement of 18F-fluorodeoxyglucose metabolism in rat brain frontal cortex using a β3 adrenoceptor agonist Activation of human brown adipose tissue by a β3-adrenergic receptor agonist.Beta3-adrenoceptor agonists: possible role in the treatment of overactive bladder Mirabegron: a safety review.Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron.Mirabegron - a selective β3-adrenoreceptor agonist for the treatment of overactive bladder New insights into the pharmacology of the bladder Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post hoc analysis of a randomized European-Australian Phase 3 trial Prospective pharmacologic therapies for the overactive bladder Do β3-adrenergic receptors play a role in guinea pig detrusor smooth muscle excitability and contractility?Mirabegron relaxes urethral smooth muscle by a dual mechanism involving β3 -adrenoceptor activation and α1 -adrenoceptor blockade New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA.Functional BK channels facilitate the β3-adrenoceptor agonist-mediated relaxation of nerve-evoked contractions in rat urinary bladder smooth muscle isolated strips.Beta-3 adrenergic agonists reduce pulmonary vascular resistance and improve right ventricular performance in a porcine model of chronic pulmonary hypertension.Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies.A functional analysis of the influence of β3-adrenoceptors on the rat micturition cycle Impact of mirabegron extended-release on the treatment of overactive bladder with urge urinary incontinence, urgency, and frequency.Pharmacotherapy of overactive bladder in adults: a review of efficacy, tolerability, and quality of life.High satisfaction with direct switching from antimuscarinics to mirabegron in patients receiving stable antimuscarinic treatment.Pharmacokinetics of mirabegron, a β3-adrenoceptor agonist for treatment of overactive bladder, in healthy Japanese male subjects: results from single- and multiple-dose studies.Preclinical compounds for the treatment of overactive bladder.The link between vascular dysfunction, bladder ischemia, and aging bladder dysfunction.On the Site and Mechanism of Action of β3-Adrenoceptor Agonists in the Bladder β(3)-Adrenoceptor ligand development history through patent review.Use of mirabegron in treating overactive bladder.Treatment of overactive bladder symptoms beyond antimuscarinics: current and future therapies.The pharmacokinetic evaluation of mirabegron as an overactive bladder therapy option.β3-receptor agonists for overactive bladder--new frontier or more of the same?Mirabegron: β3-adrenergic receptor agonist for the treatment of overactive bladder.What do we know and not know about mirabegron, a novel β3 agonist, in the treatment of overactive bladder?Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability.

P2860

Q24617239-8D001261-1089-4C38-868F-E578868AB74B Q24648758-FD10C9EB-679D-451D-93D4-FDEFE6024785 Q26770419-6805A710-9EA3-406B-ADCF-7D4613D091C4 Q26774736-86FA79F7-9276-46DA-9FC8-44DF7B0D9814 Q26780197-DA91F067-4FFA-43E0-9C79-1E191F81938A Q26783536-2D6FEF43-53C5-4094-A70F-260CEF0E9F44 Q28081739-373F8E53-8B44-4692-AB27-F4922D29CFD3 Q33659194-8DE30CB0-796E-4695-8698-412F8619A469 Q34405906-33839335-1DAA-4045-B626-A1D16A5FBDE5 Q34445014-F7FDDCF6-FAA1-4865-9CFF-FE16D2EAFD41 Q34456901-45F67A1E-137D-4F7D-912D-E8A3ED334BF5 Q34468669-DF93C132-520B-436C-9C44-282396B418BD Q34625687-395624B0-6BB9-4F12-B0AA-EC2E205808C0 Q34645986-459BF74E-D31A-446C-A7D3-AC0D863FE64A Q34657220-2FD9779C-1B56-4EDC-BC2D-D2C8A477F2DE Q34931019-33F176E6-5882-409E-9321-02FBA0B91BCF Q34991783-E9D26960-2131-4061-9700-9003413EB998 Q35076367-97B277B2-224A-477C-9E75-9CDCE80B23AF Q35924494-DA160127-14C1-4212-903F-BE5B693D3FBD Q36506889-A1BB6C3A-1C32-442C-884F-D9A50C951A8F Q36789948-C289F1D4-63D7-4AC2-B271-0E424079CD83 Q36920455-479FDE79-F64D-49BF-958C-97819783BC81 Q37026891-3D5EF820-886A-494E-B6E1-849DA4210344 Q37119868-A2D92D88-C380-4920-85C8-212347FCAEF6 Q37252037-B2B9D25C-CE74-4ECB-A1A5-6E655C2E79F9 Q37306067-6E40EDB3-2361-4CED-B5DA-1BD8143674E4 Q37390990-DFACD3F7-4B07-48E0-A2E8-9E1B4D460933 Q37409521-620708EF-6978-4A8E-BB03-B91768635C03 Q37432115-47DD57B3-92DE-4E08-96E0-5A04D1EF5224 Q37481272-2E3764DB-6D45-4A38-B121-F03F861DF281 Q37514602-25969B6D-FD7D-4C26-A140-423F433C0F06 Q37737698-CD4D41A7-E120-4604-B5D0-85B4A1BC068A Q37853580-6A60FC9F-0660-4560-B590-0296A0A60456 Q37992887-4A8AF9D4-C9A0-4213-B84C-E1178D71081F Q38018206-5BBD0701-BA65-40CE-BB52-D805FEBD7118 Q38095546-DC1BE93A-255E-413F-8704-92E37E2B5D5D Q38107167-072FFC36-599A-4439-9BE0-4E2310864D07 Q38113772-8A2E1991-A30E-4D45-AF1C-DE133C5705D7 Q38127144-C706FF3B-D26A-4C3A-BEF1-489BB4F9C30A Q38152756-E9F18E26-2B8D-47ED-B313-062DEC786C77

P2860

Effect of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function.

http://www.wikidata.org/entity/Q34575231

description

2007 nî lūn-bûn

@nan

2007 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Effect of (R)-2-(2-aminothiazo ...... agonist, on bladder function.

@ast

Effect of (R)-2-(2-aminothiazo ...... agonist, on bladder function.

@en

Effect of (R)-2-(2-aminothiazo ...... agonist, on bladder function.

@nl

type

label

Effect of (R)-2-(2-aminothiazo ...... agonist, on bladder function.

@ast

Effect of (R)-2-(2-aminothiazo ...... agonist, on bladder function.

@en

Effect of (R)-2-(2-aminothiazo ...... agonist, on bladder function.

@nl

prefLabel

Effect of (R)-2-(2-aminothiazo ...... agonist, on bladder function.

@ast

Effect of (R)-2-(2-aminothiazo ...... agonist, on bladder function.

@en

Effect of (R)-2-(2-aminothiazo ...... agonist, on bladder function.

@nl

P1433

Q34575231-D5D4C4B9-5599-4FD2-9481-F4BAF1C66D16

P1476

Q34575231-3482198A-24FD-41C5-B901-18AEF5F79255

P2093

Q34575231-25EF2411-E0F4-4EB2-A181-079F77166D96

Q34575231-6044BCDF-717D-4473-AA3D-FE59A4A3E50C

Q34575231-81F2BF74-D3C6-440C-A58D-422DF1F1B2EE

Q34575231-8A44B37B-3290-4C70-B2F0-83BD98AE98EB

Q34575231-929D2D25-E818-4A46-81ED-5AA4BC0C2C6F

Q34575231-AA23F663-2D21-46FC-AF86-8D589E43FE98

Q34575231-D9808172-5C78-45F7-9EF1-C69A17163D39

Q34575231-DBB02A1A-B469-4A50-AE70-2013959FF531

Q34575231-DF93DF13-5B5D-427B-9106-CFB03F6C4C2E

Q34575231-EBF15E8F-164F-41A3-B1E2-0A2C70A905D1

P304

Q34575231-6D99EACA-54B5-43BF-BFD4-279947C5400E

P31

Q34575231-B050BC0F-6AA9-41D7-A2E5-19DEBB62394B

P356

Q34575231-C2689F0A-F549-4536-BF0F-FC1C62A5BB26

P407

Q34575231-5B595F09-1BE2-4D3D-90B5-F13FB5FC0DFB

P433

Q34575231-51F8B06A-C298-439A-9641-2B9B5D252A58

P478

Q34575231-71A63930-CECC-4BE6-BC6E-383130AA586B

P577

Q34575231-FAA0EBB7-2137-4AB5-ADDA-13314C00FDBC

P698

Q34575231-D5D820E3-A64D-483E-9F0A-1C515369F526

P356

JPET.106.115840

P1433

Journal of Pharmacology and Experimental Therapeutics

P1476

Effect of (R)-2-(2-aminothiazo ...... agonist, on bladder function.

@en

P2093

Hisashi Uchida

http://www.w3.org/2001/XMLSchema#string

Itsuro Nagase

http://www.w3.org/2001/XMLSchema#string

Keiji Miyata

http://www.w3.org/2001/XMLSchema#string

Masao Sasamata

http://www.w3.org/2001/XMLSchema#string

Masashi Ukai

http://www.w3.org/2001/XMLSchema#string

Osamu Yamaguchi

http://www.w3.org/2001/XMLSchema#string

Shuichi Sato

http://www.w3.org/2001/XMLSchema#string

Tatsuya Maruyama

http://www.w3.org/2001/XMLSchema#string

Tetsuo Matsui

http://www.w3.org/2001/XMLSchema#string

Toshiyuki Takasu

http://www.w3.org/2001/XMLSchema#string

P304

642-647

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1124/JPET.106.115840

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

321

http://www.w3.org/2001/XMLSchema#string

P577

2007-02-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17293563

http://www.w3.org/2001/XMLSchema#string